Autor: "Sehn, Laurie H." - OpacWWW

Skocz do pozycji: 1.

Tytuł:: A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
Autorzy:: Sehn LH; BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada. .
Martelli M; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Trněný M; Charles University General Hospital, Prague, Czech Republic.
Liu W; Roche Pharma Development, Shanghai, China.
Bolen CR; Genentech, Inc., South San Francisco, CA, USA.
Knapp A; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Sahin D; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Sellam G; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Vitolo U; Candiolo Cancer Institute, FPO-IRCCS, (Turin), Candiolo, Italy.; Pokaż więcej
Źródło:: Journal of hematology & oncology [J Hematol Oncol] 2020 Jun 06; Vol. 13 (1), pp. 71. Date of Electronic Publication: 2020 Jun 06.
Typ publikacji:: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Progression-Free Survival ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Vincristine/administration & dosage ; Vincristine/adverse effects ; Young Adult
SCR Protocol:: CHOP protocol

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
Autorzy:: Lee LJ; a Department of Medicine, Division of Hematology , University of British Columbia , Vancouver , Canada.
Toze CL; b Leukemia/BMT Program of BC, Vancouver General Hospital, BC Cancer Agency and University of British Columbia , Vancouver , Canada.
Huang SJT; b Leukemia/BMT Program of BC, Vancouver General Hospital, BC Cancer Agency and University of British Columbia , Vancouver , Canada.
Gillan TL; c Department of Laboratory Medicine, Medical Genetics Laboratory , Eastern Health , St. John's , Canada.
Connors JM; d Centre for Lymphoid Cancer, BC Cancer Agency, University of British Columbia , Vancouver , Canada.
Sehn LH; d Centre for Lymphoid Cancer, BC Cancer Agency, University of British Columbia , Vancouver , Canada.
Bruyere H; e Department of Pathology and Laboratory Medicine , Vancouver General Hospital, University of British Columbia , Vancouver , Canada.
Leitch H; f Division of Hematology , St. Paul's Hospital, University of British Columbia , Vancouver , Canada.
Ramadan KM; f Division of Hematology , St. Paul's Hospital, University of British Columbia , Vancouver , Canada.
Gerrie AS; b Leukemia/BMT Program of BC, Vancouver General Hospital, BC Cancer Agency and University of British Columbia , Vancouver , Canada.; d Centre for Lymphoid Cancer, BC Cancer Agency, University of British Columbia , Vancouver , Canada.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2018 Jun; Vol. 59 (6), pp. 1356-1363. Date of Electronic Publication: 2017 Oct 16.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell/*mortality
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; British Columbia/epidemiology ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology ; Male ; Middle Aged ; Population Surveillance ; Practice Patterns, Physicians' ; Prognosis ; Registries ; Rituximab/administration & dosage ; Survival Analysis ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study .
Autorzy:: Skamene T; a Canadian Cancer Trials Group, Queen's University , Kingston , Canada.
Crump M; b Princess Margaret Cancer Centre , Toronto , Canada.
Savage KJ; c Centre for Lymphoid Cancer, BC Cancer Agency , Vancouver , Canada.
Reiman T; d Department of Medicine , Dalhousie University , Halifax , Canada.; e Department of Biology , University of New Brunswick , Saint John , Canada.; f Saint John Regional Hospital , Saint John , Canada.
Kuruvilla J; b Princess Margaret Cancer Centre , Toronto , Canada.
Good D; g Department of Pathology & Molecular Medicine , Queen's University , Kingston , Canada.
LeBrun D; g Department of Pathology & Molecular Medicine , Queen's University , Kingston , Canada.
Meyer RM; h Department of Oncology , Juravinski Hospital and Cancer Centre, McMaster University , Hamilton , Canada.
Sehn LH; c Centre for Lymphoid Cancer, BC Cancer Agency , Vancouver , Canada.
Soulières D; i Centre Hospitalier de l'Université de Montréal , Montréal , Canada.
Stakiw J; j Saskatoon Cancer Centre , Saskatoon , Canada.
Laferriere N; k Department of Oncology , Thunder Bay Regional Health Sciences, Lakehead University , Thunder Bay , Canada.
Luminari S; l Hematology , Arcispedale Santa Maria Nuova IRCCS, University of Modena and Reggio Emilia , Reggio Emilia , Italy.
Shepherd LE; a Canadian Cancer Trials Group, Queen's University , Kingston , Canada.; g Department of Pathology & Molecular Medicine , Queen's University , Kingston , Canada.
Djurfeldt M; a Canadian Cancer Trials Group, Queen's University , Kingston , Canada.
Zhu L; a Canadian Cancer Trials Group, Queen's University , Kingston , Canada.
Chen BE; a Canadian Cancer Trials Group, Queen's University , Kingston , Canada.
Hay AE; a Canadian Cancer Trials Group, Queen's University , Kingston , Canada.; m Department of Medicine , Queen's University , Kingston , Canada.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2017 Oct; Vol. 58 (10), pp. 2319-2327. Date of Electronic Publication: 2017 May 15.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Hematopoietic Stem Cell Transplantation*
Lymphoma, T-Cell, Peripheral*/drug therapy
Salvage Therapy*
Cisplatin/administration & dosage ; Cytarabine/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Humans ; Transplantation, Autologous ; Gemcitabine

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
Autorzy:: Moccia AA; a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
Hitz F; a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
Hoskins P; a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
Klasa R; a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
Power MM; b Leukemia/Bone Marrow Transplantation Program, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
Savage KJ; a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
Shenkier T; a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
Shepherd JD; b Leukemia/Bone Marrow Transplantation Program, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
Slack GW; c Department of Pathology, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
Song KW; b Leukemia/Bone Marrow Transplantation Program, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
Gascoyne RD; c Department of Pathology, British Columbia Cancer Agency , The University of British Columbia , Vancouver , BC , Canada.
Connors JM; a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.
Sehn LH; a Centre for Lymphoid Cancer, British Columbia Cancer Agency, The University of British Columbia , Vancouver , BC , Canada.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2017 Feb; Vol. 58 (2), pp. 324-332. Date of Electronic Publication: 2016 Jun 27.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Hodgkin Disease/*drug therapy
Hodgkin Disease/*pathology
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Lymphoma, Large B-Cell, Diffuse/*pathology
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin ; Deoxycytidine/analogs & derivatives ; Dexamethasone ; Drug Resistance, Neoplasm ; Female ; Hodgkin Disease/mortality ; Humans ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; Neoplasm Staging ; Recurrence ; Retreatment ; Retrospective Studies ; Salvage Therapy ; Treatment Outcome ; Young Adult ; Gemcitabine